Format

Send to

Choose Destination
Leuk Res. 2014 Dec;38(12):1392-8. doi: 10.1016/j.leukres.2014.09.016. Epub 2014 Oct 5.

How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review.

Author information

1
Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy. Electronic address: breccia@bce.uniroma1.it.
2
Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

Abstract

Tyrosine kinase inhibitors (TKIs) advent has deeply changed the outcome of chronic myeloid leukemia (CML) patients, with improved rates of response and overall survival. However, for this success some patients paid the price of a number of peculiar side effects, the so-called off-target side effects, specific for each one TKI. These effects are due to non-selective inhibition of other tyrosine kinase receptors, such as PDGFR, c-KIT, Src, VEGF. Consequences of this inhibition, some metabolic changes during the treatment with TKIs are reported. Aim of present review is to report metabolic changes and potential mechanisms involved in the pathogenesis related to imatinib, second (nilotinib and dasatinib) and third generation (bosutinib and ponatinib) TKIs.

KEYWORDS:

Endocrine; Metabolic; Tyrosine kinase inhibitors

PMID:
25449685
DOI:
10.1016/j.leukres.2014.09.016
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center